Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Price Hikes Protect Cephalon, Lining Up Nuvigil Ducks

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm to add sales reps after ending Takeda co-promotion deal.

You may also be interested in...



Panel COVERS Problems With Cephalon’s Fentora

Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.

Amrix And Treanda Take-up Bodes Well For Cephalon

New drugs help firm move on from fading Actiq, beset by generic erosion.

FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel